SynthesisWorld journal of gastroenterology2015
Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.
Synthesis in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.Antimicrobial agents and chemotherapy · 2017Trial
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- Efficacy and safety of Qingwei Zhitong pellets-containing quadruple therapy for eradication: a prospective, single-center, randomized trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Therapeutic advances and future directions inFrontiers in microbiology · 2025Review
- The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial.Infectious diseases and therapy · 2023Article
- Evolution ofAntibiotics (Basel, Switzerland) · 2023Review
- Update on the first-line treatment ofTherapeutic advances in gastroenterology · 2022Review
- Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- The status and progress of first-line treatment againstTherapeutic advances in gastroenterology · 2021Review
- Recent progress in Helicobacter pylori treatment.Chinese medical journal · 2020Review
- CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy forWorld journal of clinical cases · 2018Article
- Toward population specific and personalized treatment of Helicobacter pylori infection.Journal of biomedical science · 2018Review
- The Prevalence and Risk Factors of Gastric Polyp in Asymptomatic Patients Receiving Health Examination.Gastroenterology research and practice · 2018Article
- A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Advances in therapy · 2017Review
- Update on the first-line treatment forBiomarker research · 2017Review
- Eradication of Helicobacter pylori Infection.Current gastroenterology reports · 2016Review
- Hybrid Therapy Regimen for Helicobacter Pylori Eradication.Chinese medical journal · 2016Review
- Optimal First-Line Treatment forGastroenterology research and practice · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare the effectiveness of hybrid therapy with other recommended regimens using meta-analysis.
methodsBibliographical searches for randomized trials comparing hybrid and other therapies were performed in PubMed, the Cochrane Library and relevant congresses up to February 2015 using the following keywords (all fields and/or MeSH): ("Helicobacter pylori" or "H. pylori") and ("hybrid therapy" or "sequential-concomitant therapy"). Meta-analyses were performed with Cochrane Review Manager 5.1. The random effect model proposed by DerSimonian and Laird and the Mantel-Haenszel method were used to estimate the pooled relative risk and 95%CI of the efficacy outcomes between hybrid therapy and other eradication therapies.
resultsEight studies (2516 subjects) met entry criteria. The antimicrobial resistance in the study groups ranged from 6.9% to 23.5%. The mean cure rates of hybrid therapy by intention-to-treat (ITT) and per-protocol analyses were 88.5% (n = 1207; range: 80.0% to 97.4%) and 93.3% (n = 1109; range: 85.7% to 99.1%), respectively. Meta-analysis showed there was no significant difference in ITT eradication rate between hybrid and sequential therapy (relative risk: 1.01; 95%CI: 0.92-1.11). Subgroup analysis revealed hybrid therapy was more effective than sequential therapy in the non-Italian populations (95%CI: 1.01-1.18) and was only less effective in one, Italian population (95%CI: 0.83-0.98). There was no significant difference in eradication rate between hybrid therapy and concomitant therapy (95%CI: 0.93-1.02). No head-to-head comparisons of hybrid therapy and standard triple therapy or bismuth quadruple therapy were found. However, a multicenter, randomized trial showed that reverse hybrid therapy was superior to standard triple therapy (95.5% vs 88.6% ITT; P = 0.011).
conclusionHybrid therapy appears to be an effective, safe, and well-tolerated treatment for H. pylori infection in the era of increasing antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.